Zealand Pharma Announces First Subject Dosed in Phase 1 Trial of Amylin Analogue ZP8396 for the Treatment of Obesity

https://www.globenewswire.com/news-release/2021/11/04/2327572/0/en/Zealand-Pharma-Announces-First-Subject-Dosed-in-Phase-1-Trial-of-Amylin-Analogue-ZP8396-for-the-Treatment-of-Obesity.html

company announcement